ZLNA ZELLUNA ASA

Zelluna ASA: Cancellation of subsequent repair offering

Zelluna ASA: Cancellation of subsequent repair offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 9 December, 2025: Reference is made to the stock exchange announcement published by Zelluna ASA ("Zelluna" or the "Company") on 3 November 2025 regarding the private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering"), depending, inter alia, on the development of the price of the shares in the Company after completion of the Private Placement.

The board of directors of the Company has resolved not to proceed with the Subsequent Offering.

The background for the cancellation is that the Company's shares have traded at or below the subscription price in the Private Placement for an extended period of time and at sufficient volumes. Shareholders wishing to reduce the dilutive effect of the Private Placement have thus had the opportunity to purchase shares in the market at prices at or below the price which would have been the subscription price in the Subsequent Offering.

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA

Email: 

Phone:

Hans Vassgård Eid, CFO, Zelluna ASA

Email: 

Phone:



EN
09/12/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE

Zelluna Reaches Major Milestone and Submits Clinical Trial Application...

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours On track for initial clinical data in mid-2026Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulat...

 PRESS RELEASE

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk stu...

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer. Forventer første kliniske data fra midten av 2026Markerer et viktig skritt mot skalerbare, tilgjengelige "off-the-shelf" celleterapier for solide kreftformer Oslo, Norge, 17. desember 2025 – Zelluna (OSE: ZLNA), et bioteknologiselskap som utvikler allogene "off-the-shelf" celleterapier mot kreft, kunngjorde i dag at selskapet har innlevert søknad om oppstart av klinisk studi...

 PRESS RELEASE

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World'...

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances*. The data support the company's plan to start clinical trials in 2026. The paper describes ZI-MA4-1, a novel cell therapy that combines tw...

 PRESS RELEASE

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell The...

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important step in developing scalable and accessible ‘off-the-shelf’ cell therapy for patients with solid tumours Oslo, Norway, 12 December, 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the successful manufacture and Q...

 PRESS RELEASE

Zelluna ASA: Cancellation of subsequent repair offering

Zelluna ASA: Cancellation of subsequent repair offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Oslo, 9 December, 2025: Reference is made to the stock exchange announcement published by Zelluna ASA ("Zelluna" or the "Company") on 3 November 2025 regarding the private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering"), depending, inter alia, on...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch